All News
Today is July 21, 2018.
All times in Eastern Daylight Time.
-
Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported first quarter 2018 financial results. more » -
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert will report its first quarter 2018 financials on May 3, 2018, and present at several upcoming investor conferences. more » -
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert announced that it completed patient enrollment in its Phase 2a trial evaluating CTP-543 for alopecia areata. more » -
Concert Pharmaceuticals Present at Upcoming Investor Conferences
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert is scheduled to present at the upcoming Cowen, Oppenheimer and H.C. Wainwright healthcare conferences. more » -
Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported financial results for the year ended December 31, 2017, and provided an update on its product pipeline and corporate activities. more » -
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert selected CTP-692 for adjunctive treatment of schizophrenia, a chronic illness with significant unmet need, as its next development candidate. more » -
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursd... more » -
Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
LEXINGTON, Mass.--(EON: Enhanced Online News)--The Company initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543 for the treatment of alopecia areata. more » -
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
LEXINGTON, Mass.--(EON: Enhanced Online News)--FDA has granted Fast Track designation for CTP-543, a novel, JAK inhibitor for the treatment of moderate-to-severe alopecia areata. more » -
Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
LEXINGTON, Mass.--(EON: Enhanced Online News)--PTAB decided not to grant the Company’s PGR petition. more » -
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
LEXINGTON, Mass.--(EON: Enhanced Online News)--Marc Becker will join Concert as Chief Financial Officer, effective January 4, 2018. more » -
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert has been selected for addition to the NBI effective prior to the market open on December 18, 2017 more » -
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert third quarter of 2017 financial results. more » -
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543 for alopecia areata. more » -
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert will report third quarter financial results on November 9th. The Company is also scheduled to participate at several healthcare conferences. more » -
Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
LEXINGTON, Mass.--(EON: Enhanced Online News)--Incyte’s IPR petition challenging Concert's CTP-543 patent was denied by PTAB. more » -
Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert to present at Wells Fargo Securities 2017 Healthcare Conference on September 7, 2017. more » -
Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported financial results for the second quarter of 2017. more » -
Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017,... more » -
Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex
LEXINGTON, Mass.--(EON: Enhanced Online News)--The FTC has terminated the waiting period under the HSR Act for the pending sale of CTP-656 by Concert to Vertex. more »
Contact Us
For more information, visit the Contact Us page of BusinessWire.com to find a bureau near you.